FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2588413111> ?p ?o ?g. }

• W2588413111 endingPage "iv18" @default.
• W2588413111 startingPage "iv18" @default.
• W2588413111 abstract "Background: TCF is one of the most effective first-line options in metastatic GEC. We previously reported the significant activity of mTCF-dd (Tomasello G et al: Gastric Cancer 2014 Oct;17(4):711-7). Aim of this study is to describe clinical outcomes, safety and studying potential clinical prognostic factors of this intensified regimen in a very large consecutive cohort of pts coming from a single center Methods: 201 consecutive pts with measurable or evaluable GEC treated in the same institution were longitudinally followed. 136 were enrolled in 3 different Clinical Trials and 65 treated according to clinical practice. We considered pts with PS ECOG 0-2 and adequate organ function who received from 2004 to 2015 mTCF-dd: Docetaxel (50-85 mg/m2 d 1), Cisplatin (50-75 mg/m2 d 1),l-Folinic Acid (100 mg/m2 d 1-2), 5-FU (400 mg/m2 bolus d 1-2, and 600 mg/m2 as a 44 h c.i. d 1), plus Pegfilgrastim 6 mg d 3, q2w. Analysis was done according to ITT principle. Results: Median age was 63 (range 25-81), M:F 140:51. Metastatic sites were: liver 38%, peritoneum 33.5%, bone 14%, lung 12%. A median of 4 cycles (range 1-8) per patient were administered: 15% required a dose reduction, 48% were treated without any delay. At a median follow up of 60 months, 192 pts were evaluable. We observed 6% CR, 52% PR, 14% SD, 13% PD and 13% NE, for an ORR of 59% (95% CI 52-66); DCR was 76%. Median OS was 11.1 months (95% CI 9.5-13.5). Most frequent grade 3/4 toxicities: neutropenia (26%), asthenia (31%), thrombocytopenia (17%), hypokalemia (16%), diarrhea (13%), febrile neutropenia (11%). 18 pts (9%) became resectable after mTCF-dd and underwent surgery. Finally, we identified 18 pts (9%) [12 metastatic, 6 locally advanced] with OS > 3 years and 7 (4%) still maintaining a response at the time of the current analysis. Moreover, we identified a specific cohort of 21 pts with bone metastases at diagnosis bearing a very poor prognosis (OS: 7.8 m 95% CI 3.8-10). A multivariate Cox model will be presented at the meeting. Conclusions: mTCF-dd in GEC is an effective and feasible option. A careful monitoring of adverse events is recommended. A biomolecular analysis of long-term survivors is underway." @default.
• W2588413111 created "2017-02-24" @default.
• W2588413111 creator A5004680827 @default.
• W2588413111 creator A5011322435 @default.
• W2588413111 creator A5013554030 @default.
• W2588413111 creator A5039987253 @default.
• W2588413111 creator A5041597689 @default.
• W2588413111 creator A5066394827 @default.
• W2588413111 creator A5067193136 @default.
• W2588413111 creator A5069893430 @default.
• W2588413111 date "2016-09-01" @default.
• W2588413111 modified "2023-10-17" @default.
• W2588413111 title "Modified dose-dense taxotere cisplatin fluorouracil regimen (mTCF-dd) in a large cohort of patients (pts) with metastatic or locally advanced non-squamous gastroesophageal cancer (GEC)" @default.
• W2588413111 doi "https://doi.org/10.1093/annonc/mdw333.05" @default.
• W2588413111 hasPublicationYear "2016" @default.
• W2588413111 type Work @default.
• W2588413111 sameAs 2588413111 @default.
• W2588413111 citedByCount "0" @default.
• W2588413111 crossrefType "journal-article" @default.
• W2588413111 hasAuthorship W2588413111A5004680827 @default.
• W2588413111 hasAuthorship W2588413111A5011322435 @default.
• W2588413111 hasAuthorship W2588413111A5013554030 @default.
• W2588413111 hasAuthorship W2588413111A5039987253 @default.
• W2588413111 hasAuthorship W2588413111A5041597689 @default.
• W2588413111 hasAuthorship W2588413111A5066394827 @default.
• W2588413111 hasAuthorship W2588413111A5067193136 @default.
• W2588413111 hasAuthorship W2588413111A5069893430 @default.
• W2588413111 hasBestOaLocation W25884131111 @default.
• W2588413111 hasConcept C121608353 @default.
• W2588413111 hasConcept C126322002 @default.
• W2588413111 hasConcept C141071460 @default.
• W2588413111 hasConcept C2776694085 @default.
• W2588413111 hasConcept C2777063308 @default.
• W2588413111 hasConcept C2778336483 @default.
• W2588413111 hasConcept C2779804826 @default.
• W2588413111 hasConcept C2780456651 @default.
• W2588413111 hasConcept C2781190966 @default.
• W2588413111 hasConcept C2781413609 @default.
• W2588413111 hasConcept C71924100 @default.
• W2588413111 hasConcept C72563966 @default.
• W2588413111 hasConcept C90924648 @default.
• W2588413111 hasConceptScore W2588413111C121608353 @default.
• W2588413111 hasConceptScore W2588413111C126322002 @default.
• W2588413111 hasConceptScore W2588413111C141071460 @default.
• W2588413111 hasConceptScore W2588413111C2776694085 @default.
• W2588413111 hasConceptScore W2588413111C2777063308 @default.
• W2588413111 hasConceptScore W2588413111C2778336483 @default.
• W2588413111 hasConceptScore W2588413111C2779804826 @default.
• W2588413111 hasConceptScore W2588413111C2780456651 @default.
• W2588413111 hasConceptScore W2588413111C2781190966 @default.
• W2588413111 hasConceptScore W2588413111C2781413609 @default.
• W2588413111 hasConceptScore W2588413111C71924100 @default.
• W2588413111 hasConceptScore W2588413111C72563966 @default.
• W2588413111 hasConceptScore W2588413111C90924648 @default.
• W2588413111 hasLocation W25884131111 @default.
• W2588413111 hasOpenAccess W2588413111 @default.
• W2588413111 hasPrimaryLocation W25884131111 @default.
• W2588413111 hasRelatedWork W1791924137 @default.
• W2588413111 hasRelatedWork W2000050818 @default.
• W2588413111 hasRelatedWork W2133332025 @default.
• W2588413111 hasRelatedWork W2240637203 @default.
• W2588413111 hasRelatedWork W2417931553 @default.
• W2588413111 hasRelatedWork W2509837252 @default.
• W2588413111 hasRelatedWork W2599610220 @default.
• W2588413111 hasRelatedWork W2777147237 @default.
• W2588413111 hasRelatedWork W2999789808 @default.
• W2588413111 hasRelatedWork W2186909195 @default.
• W2588413111 hasVolume "27" @default.
• W2588413111 isParatext "false" @default.
• W2588413111 isRetracted "false" @default.
• W2588413111 magId "2588413111" @default.
• W2588413111 workType "article" @default.